Equities research analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a "sell" rating on the stock.
Ayala Pharmaceuticals Price Performance
About Ayala Pharmaceuticals
(Get Rating)
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Featured Stories
- Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (ADXS)
- On Holding AG Sprints Higher on Margin Expansion and Guidance
- Price Growth & Yield: For That Magical Combo, Leave the U.S.
- Game-Changing News For Tesla Investors
- DOW New Hghs Coming Sooner Than Later
- The Tide Is Turning For Harley-Davidson
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.